By: ICN Bureau
Last updated : October 10, 2025 5:10 pm
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
Jubilant Pharmova Limited announced today that Jubilant HollisterStier LLC (JHS), specialising in sterile injectables, launched its new sterile fill & finish line, third at its Spokane manufacturing facility in Washington, US.
The launch was marked by the successful production of the inaugural batch, initiating revenue generation from the new line. This milestone denotes a significant advancement in Jubilant HollisterStier’s multi-phase expansion strategy and brings an additional 50 per cent capacity at its Spokane manufacturing facility.
The new line features highest global regulatory standards and advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision.
The US$ 132 million investment towards this new third line reflects the JHS’s long-term commitment to innovation, quality and supply chain resilience.
Together with the commissioning of its upcoming Fourth Line, JHS is on track to double its total sterile injectable manufacturing capacity at its Spokane facility in the US. This strategic investment further reinforces JHS’ leadership in domestic US pharmaceutical manufacturing. By expanding its infrastructure and increasing onshore capacity, the Company is contributing to US national health security and helping to reduce reliance on offshore supply chains— delivering a more resilient and agile pharmaceutical manufacturing ecosystem.
Commenting on the development, Chris Preti, CEO - CDMO Sterile Injectables said, “It’s a defining moment in Jubilant HollisterStier’s journey. This expansion also reflects our deep-rooted commitment, to continued growth, technological excellence and the community at Spokane. With Third Line now operational and Fourth Line on the horizon, we are not just doubling our capacity, we’re building a future that will create hundreds of new jobs, strengthen the US pharmaceutical supply chain and reaffirm our role as a trusted partner in delivering life-saving therapies to patients around the world.”
He further added, “In the wake of new tariffs imposed by the US Government, large innovator pharma companies are looking for high quality, US manufacturing facilities. Therefore, we are witnessing a very strong traction in Requests for Proposals (RFPs) for the New Line. We expect to reach the full utilisation for the New Line in the next 3 years.”